Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury

Figure 1

(a) Impact of Anakinra and erythropoietin on infarct size. One-time intravenous administration of Anakinra prior to reperfusion resulted in a significant reduction of infarct size expressed as infarct mass in relation to area at risk mass (%) compared to controls or animals receiving erythropoietin (*𝑃<0.05, 𝑁=4/group). (b) Impact of Anakinra and erythropoietin on area at risk. One-time intravenous administration of Anakinra or erythropoietin prior to reperfusion did not significantly influence area at risk (n.s. = non significant, 𝑁=4/group).

(a)

(b)